There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
Market Cap
18454.39 Cr.Face value
-Book value
-Div. yield
-P/E ratio
-P/B ratio
-Debt/Eq.
-Market Cap
18454.39 Cr.Face value
-Book value
-Div. yield
-%P/E ratio
-P/B ratio
-Debt/Eq.
-
| Mar 26 | Dec 25 | Change | |
|---|---|---|---|
| Promoter Holdings | 53.92% | 54.85% | -0.93% |
| Promoter Pledge | 16.92% | 16.92% | 0.00% |
Eris Lifesciences Limited founded by Amit Bakshi and team in 2007 is one of the fastest growing companies within the chronic and acute categories of the Indian Branded Formulations market such as: cardiovascular; anti–diabetes; vitamins; gastroentero 
Eris manufactures and markets prescription pharmaceuticals across specialty and super-specialty therapies, with leadership in cardio-metabolic care and growing portfolios in Dermatology, Women’s Health, Critical Care, Nephrology and Oncology .
As on March 31, 2025, Eris had 8 subsidiaries and 1 joint venture; only the number is disclosed here in line with your request .
The Group operates manufacturing across six globally accredited/compliant units in India, with facilities designed for EU-GMP, PIC/s and Latin American compliance; Swiss Parenterals is the international arm as Eris expands to RoW exports. Its Ahmedabad units were inspected by ANVISA, reflecting readiness for large international markets .
